BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Drop in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTXW) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 2,900 shares, a decrease of 77.3% from the November 30th total of 12,800 shares. Based on an average trading volume of 158,000 shares, the short-interest ratio is currently 0.0 days.

BriaCell Therapeutics Stock Performance

BCTXW traded down $0.01 during trading on Friday, reaching $0.28. 53,515 shares of the company were exchanged, compared to its average volume of 86,532. BriaCell Therapeutics has a 12-month low of $0.11 and a 12-month high of $2.60. The company’s 50-day moving average is $0.34 and its two-hundred day moving average is $0.28.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.